Toxicity Attribution in Phase I Trials

Currently, Phase I designs use the presence of Dose Limiting Toxicities (DLT) to guide dose escalation and de-escalation. The assumption is that this DLT outcome is observed without error.  This presentation will illustrate the impact of toxicity attribution errors on Phase I designs and the recommended Phase II dose, and discuss the statistical and clinical implications of misclassification errors (false DLTs). Potential solutions to the problem will also be presented.

Audience

This program is for the research community.

Date & Time(s)

Location

307 East 63rd Street
3rd Floor Conference Room
New York, NY 10065

Sponsor(s)

Department of Epidemiology and Biostatistics